Compounders Research Compare

Nkarta, Inc.(NKTX)

Biotechnology · South San Francisco, CA

$2.34-0.19 (-7.37%)

Delayed quote: Oct 6, 2026, 3:05 PM EDT

About Nkarta, Inc.

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.

South San Francisco, CA

106 employees

www.nkartatx.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Paul J. Hastings

View full financials

Nkarta (NKTX) EV/EBITDA: History & Chart | TGMCharts

EV/EBITDA Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/EBITDA ratio is N/A as of 2026-10-06T19:12:53.072Z.

Stored calculation inputs

Calculation as of: 2026-10-06T19:12:53.072Z.

Quote observation: 2026-10-06T19:10:03.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 165,985,231
Total debt · period ending 2026-06-30: 73,539,000
Cash · period ending 2026-06-30: 24,958,000
TTM operating EBITDA · period ending 2026-06-30: -122,616,000

FMP input reference: bddae1a009f0b40e7fb659cb125a310776fd64778f9839bff19075a224db575c

EV/Sales|P/E Ratio|EBITDA|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

NKTX EV/EBITDA Ratio Metrics

EV/EBITDA RATIO

N/A

NKTX Competitors' EV/EBITDA Ratio

Nkarta, Inc.

Current

Market Cap

$165.99M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

MediWound Ltd.

Market Cap

$168.97M

EV/EBITDA Ratio

N/A

TTM Avg

7.02x

3Y Avg

7.02x

5Y Avg

7.02x

OptimizeRx Corp.

Market Cap

$165.70M

EV/EBITDA Ratio

10.43x

TTM Avg

86.42x

3Y Avg

168.75x

5Y Avg

173.55x

Organogenesis Holdings Inc.

Market Cap

$169.85M

EV/EBITDA Ratio

214.03x

TTM Avg

57.51x

3Y Avg

54.12x

5Y Avg

36.92x

Cue Biopharma, Inc.

Market Cap

$170.21M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Precision BioSciences, Inc.

Market Cap

$171.41M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Quanterix Corporation

Market Cap

$163.22M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Coherus Oncology, Inc.

Market Cap

$163.00M

EV/EBITDA Ratio

N/A

TTM Avg

8.39x

3Y Avg

66.32x

5Y Avg

66.32x

Journey Medical Corporation

Market Cap

$173.30M

EV/EBITDA Ratio

137.24x

TTM Avg

155.63x

3Y Avg

70.41x

5Y Avg

70.41x

ProQR Therapeutics N.V.

Market Cap

$173.76M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EV/EBITDA RATIO	TTM	3Y	5Y
Nkarta, Inc. (NKTX)	$165.99M	N/A	N/A	N/A	N/A
MediWound Ltd. (MDWD)vs ›	$168.97M	N/A	7.02x	7.02x	7.02x
OptimizeRx Corp. (OPRX)vs ›	$165.70M	10.43x	86.42x	168.75x	173.55x
Organogenesis Holdings Inc. (ORGO)vs ›	$169.85M	214.03x	57.51x	54.12x	36.92x
Cue Biopharma, Inc. (CUE)vs ›	$170.21M	N/A	N/A	N/A	N/A
Precision BioSciences, Inc. (DTIL)vs ›	$171.41M	N/A	N/A	N/A	N/A
Quanterix Corporation (QTRX)vs ›	$163.22M	N/A	N/A	N/A	N/A
Coherus Oncology, Inc. (CHRS)vs ›	$163.00M	N/A	8.39x	66.32x	66.32x
Journey Medical Corporation (DERM)vs ›	$173.30M	137.24x	155.63x	70.41x	70.41x
ProQR Therapeutics N.V. (PRQR)vs ›	$173.76M	N/A	N/A	N/A	N/A

EV/EBITDA Ratio Formula & Definition

EV/EBITDA = Enterprise Value / EBITDA (TTM)

Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

EV/Sales P/E Ratio EBITDA All Metrics